MeSH term
Frequency | Condition_Probility | Humans | 503 | 0.0 |
Animals | 75 | 0.0 |
History, 20th Century | 2 | 1.0 |
Research Support, Non-U.S. Gov't | 245 | 0.0 |
Forecasting | 2 | 0.0 |
Antibodies/pharmacology | 4 | 1.0 |
Antineoplastic Agents, Alkylating/*metabolism | 3 | 42.0 |
*Aryl Hydrocarbon Hydroxylases | 150 | 17.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 24 | 18.0 |
Enzyme Inhibitors/pharmacology | 34 | 1.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 16 | 22.0 |
Kinetics | 81 | 0.0 |
Microsomes, Liver/drug effects/*enzymology | 10 | 23.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 5 | 10.0 |
Transfection | 12 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 3 | 16.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 17 | 11.0 |
*Drug Design | 2 | 2.0 |
In Vitro | 82 | 1.0 |
Mixed Function Oxygenases/genetics/metabolism | 3 | 13.0 |
Pharmacogenetics | 6 | 5.0 |
Pharmacology, Clinical | 2 | 100.0 |
Phenotype | 22 | 0.0 |
Polymorphism, Genetic | 29 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 66 | 13.0 |
Drug Interactions | 55 | 4.0 |
Dose-Response Relationship, Drug | 28 | 0.0 |
Half-Life | 11 | 1.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Microsomes, Liver/*enzymology | 30 | 15.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 27 | 26.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
Comparative Study | 93 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 2 | 1.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Genotype | 90 | 0.0 |
Mixed Function Oxygenases/*genetics | 13 | 9.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
DNA/drug effects/*metabolism | 2 | 40.0 |
DNA Fragmentation/drug effects | 2 | 2.0 |
DNA Topoisomerases, Type I/*metabolism | 2 | 7.0 |
Enzyme Inhibitors/*pharmacology | 26 | 3.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Tumor Cells, Cultured | 17 | 0.0 |
Anti-Infective Agents/*pharmacology | 2 | 6.0 |
Chromatography, High Pressure Liquid | 50 | 2.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 17 | 24.0 |
Female | 135 | 0.0 |
Male | 161 | 0.0 |
Microsomes, Liver/drug effects/enzymology | 14 | 14.0 |
Recombinant Proteins/antagonists & inhibitors | 5 | 10.0 |
*Steroid 16-alpha-Hydroxylase | 137 | 74.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 7 | 77.0 |
Blotting, Western | 9 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cells, Cultured | 29 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 4 | 10.0 |
Gene Expression | 6 | 0.0 |
Hepatocytes/*drug effects/enzymology | 4 | 28.0 |
Protein Isoforms | 3 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Databases, Factual | 2 | 0.0 |
Quantitative Structure-Activity Relationship | 3 | 10.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 4 | 22.0 |
Isoenzymes/chemistry/metabolism | 2 | 7.0 |
Models, Molecular | 18 | 0.0 |
Base Sequence | 13 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 41 | 9.0 |
DNA Primers | 9 | 0.0 |
Oxidoreductases, N-Demethylating/*genetics | 2 | 4.0 |
Steroid Hydroxylases/*genetics | 28 | 32.0 |
Adult | 117 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 5 | 20.0 |
Asian Continental Ancestry Group | 4 | 1.0 |
Drug Therapy, Combination | 2 | 0.0 |
Metabolic Clearance Rate | 14 | 4.0 |
Mixed Function Oxygenases/genetics/*metabolism | 7 | 14.0 |
*Polymorphism, Genetic | 28 | 0.0 |
Taiwan | 2 | 1.0 |
Acetylation | 2 | 0.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Hela Cells | 2 | 0.0 |
Pharmacokinetics | 7 | 19.0 |
Inhibitory Concentration 50 | 10 | 3.0 |
Microsomes, Liver/*drug effects | 2 | 66.0 |
Alleles | 43 | 0.0 |
*Genotype | 3 | 1.0 |
Mutation | 9 | 0.0 |
Risk Factors | 7 | 0.0 |
Variation (Genetics) | 8 | 0.0 |
Analysis of Variance | 6 | 0.0 |
Area Under Curve | 27 | 5.0 |
Biotransformation | 31 | 5.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Glyburide/blood/*pharmacokinetics | 2 | 100.0 |
Polymorphism, Genetic/*genetics | 15 | 1.0 |
Flavonoids/*metabolism | 2 | 33.0 |
Mice | 7 | 0.0 |
Microsomes, Liver/enzymology | 30 | 13.0 |
Recombinant Proteins/metabolism | 32 | 1.0 |
Species Specificity | 12 | 0.0 |
Mass Fragmentography | 5 | 2.0 |
Microsomes, Liver/*metabolism | 20 | 11.0 |
Mixed Function Oxygenases/*metabolism | 12 | 8.0 |
*Monoterpenes | 2 | 20.0 |
Oxidation-Reduction | 32 | 2.0 |
Rats | 30 | 0.0 |
Stereoisomerism | 34 | 8.0 |
Steroid Hydroxylases/*metabolism | 10 | 31.0 |
Isoenzymes/metabolism | 24 | 4.0 |
Research Support, U.S. Gov't, P.H.S. | 100 | 0.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 19 | 16.0 |
Isoenzymes/antagonists & inhibitors | 5 | 12.0 |
Microsomes, Liver/drug effects/metabolism | 3 | 6.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 2 | 6.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 3 | 33.0 |
Ethanolamines/metabolism | 3 | 16.0 |
Histamine H1 Antagonists/*pharmacology | 3 | 27.0 |
Hydroxylation | 53 | 15.0 |
Steroid Hydroxylases/*antagonists & inhibitors | 4 | 57.0 |
Tolbutamide/metabolism | 10 | 66.0 |
African Continental Ancestry Group/*genetics | 4 | 1.0 |
European Continental Ancestry Group/*genetics | 9 | 2.0 |
Genetics, Population | 2 | 0.0 |
Phenytoin/pharmacology | 2 | 14.0 |
Warfarin/pharmacology | 2 | 13.0 |
English Abstract | 14 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/*metabolism | 7 | 41.0 |
Cell Fractionation | 2 | 0.0 |
Cell Line | 16 | 0.0 |
China | 3 | 0.0 |
Hypoglycemic Agents/metabolism | 2 | 50.0 |
Liver/*enzymology | 9 | 1.0 |
Recombinant Proteins/genetics/metabolism | 9 | 1.0 |
Anti-Inflammatory Agents, Non-Steroidal/chemistry/metabolism | 2 | 100.0 |
Binding Sites/genetics | 2 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Substrate Specificity | 44 | 2.0 |
European Continental Ancestry Group | 6 | 0.0 |
Middle Aged | 94 | 0.0 |
Prospective Studies | 8 | 0.0 |
Regression Analysis | 3 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 2 | 4.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Sulfaphenazole/pharmacology | 11 | 37.0 |
Mixed Function Oxygenases/immunology | 2 | 40.0 |
Steroid Hydroxylases/immunology | 2 | 66.0 |
Cross-Over Studies | 13 | 2.0 |
Drug Evaluation | 4 | 1.0 |
Heterozygote | 9 | 0.0 |
Homozygote | 9 | 0.0 |
Hypoglycemic Agents/*pharmacokinetics | 3 | 100.0 |
Single-Blind Method | 2 | 0.0 |
Insulin/blood | 2 | 0.0 |
Population Surveillance | 2 | 1.0 |
Time Factors | 18 | 0.0 |
Blood Glucose/metabolism | 3 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
Tolbutamide/*pharmacokinetics | 3 | 100.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Imidazoles/pharmacokinetics/*pharmacology | 2 | 40.0 |
Isoenzymes/antagonists & inhibitors/genetics/metabolism | 6 | 42.0 |
Adolescent | 19 | 0.0 |
Gene Frequency/genetics | 6 | 1.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Turkey | 3 | 2.0 |
International Normalized Ratio | 8 | 27.0 |
Cytochrome P-450 Enzyme System/*genetics/physiology | 2 | 28.0 |
Diclofenac/*metabolism/pharmacokinetics | 2 | 100.0 |
Microsomes, Liver/metabolism | 15 | 8.0 |
Steroid Hydroxylases/*genetics/physiology | 2 | 66.0 |
Administration, Oral | 14 | 1.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 10 | 20.0 |
Imidazoles/*pharmacokinetics | 3 | 21.0 |
Spain | 2 | 0.0 |
Steroid Hydroxylases/*genetics/*metabolism | 5 | 71.0 |
Sweden | 2 | 0.0 |
Tetrazoles/*pharmacokinetics | 2 | 100.0 |
Chromatography, High Pressure Liquid/*methods | 4 | 3.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 5 | 11.0 |
Reference Values | 10 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Spectrum Analysis, Mass/*methods | 3 | 7.0 |
Steroid Hydroxylases/genetics/metabolism | 2 | 18.0 |
Models, Chemical | 7 | 1.0 |
Oxidoreductases, N-Demethylating/*metabolism | 5 | 6.0 |
Cytochrome P-450 CYP1A2/*metabolism | 3 | 3.0 |
Pharmaceutical Preparations/*metabolism | 12 | 13.0 |
Coumarins/metabolism | 4 | 16.0 |
Cytochrome P-450 CYP2D6 | 4 | 5.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 13 | 11.0 |
NADP/metabolism | 5 | 4.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 2 | 40.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Steroid Hydroxylases/genetics | 3 | 11.0 |
Enzyme Inhibitors/metabolism/*pharmacology | 3 | 17.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Rats, Wistar | 5 | 0.0 |
DNA Adducts/*metabolism | 2 | 4.0 |
Microsomes, Liver/*drug effects/metabolism | 4 | 30.0 |
Rabbits | 13 | 0.0 |
Cytochrome P-450 Enzyme System/physiology | 2 | 7.0 |
Double-Blind Method | 6 | 0.0 |
Aged | 60 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 5 | 7.0 |
Enzyme Induction | 9 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Rifampin/*pharmacology | 4 | 8.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 5 | 10.0 |
Cytochrome P-450 CYP1A2/metabolism | 8 | 8.0 |
Sex Factors | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*physiology | 9 | 15.0 |
Hydroxylation/drug effects | 8 | 22.0 |
Microsomes, Liver/*drug effects/enzymology | 10 | 29.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 7 | 36.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 4 | 44.0 |
Anticoagulants/*administration & dosage | 3 | 7.0 |
Cohort Studies | 4 | 0.0 |
Warfarin/*administration & dosage | 3 | 33.0 |
Predictive Value of Tests | 4 | 0.0 |
DNA, Complementary/biosynthesis | 2 | 3.0 |
Haloperidol/*pharmacokinetics | 2 | 100.0 |
Microsomes, Liver/enzymology/*metabolism | 10 | 12.0 |
Gene Frequency | 7 | 0.0 |
Aged, 80 and over | 20 | 0.0 |
*Gene Expression Regulation, Enzymologic | 6 | 1.0 |
Hepatocytes/enzymology | 4 | 26.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 2 | 3.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
African Continental Ancestry Group | 3 | 1.0 |
*Genetics, Population | 3 | 0.0 |
*Cytochrome P-450 Enzyme System/genetics/metabolism/physiology | 2 | 66.0 |
Mephenytoin/metabolism | 3 | 18.0 |
Omeprazole/metabolism | 3 | 37.0 |
Phenytoin/metabolism | 2 | 50.0 |
Isoenzymes/genetics/metabolism | 8 | 5.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Saccharomyces cerevisiae/enzymology | 3 | 5.0 |
Antilipemic Agents/*pharmacology | 2 | 5.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 4 | 30.0 |
Cytochrome P-450 CYP2D6/metabolism | 10 | 25.0 |
Cytochrome P-450 CYP2E1/metabolism | 7 | 16.0 |
Mixed Function Oxygenases/metabolism | 13 | 9.0 |
Electron Transport Complex IV/*metabolism | 2 | 11.0 |
Plant Proteins/*metabolism | 2 | 20.0 |
Genetic Engineering | 2 | 2.0 |
Mutagenicity Tests | 3 | 1.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 3 | 42.0 |
Enzyme Induction/drug effects | 12 | 3.0 |
Oxidoreductases, N-Demethylating/biosynthesis | 2 | 25.0 |
RNA, Messenger/biosynthesis/drug effects | 2 | 3.0 |
Rifampin/pharmacology | 4 | 6.0 |
Liver/drug effects/*enzymology | 2 | 5.0 |
Microsomes/metabolism | 7 | 5.0 |
Molecular Sequence Data | 18 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 2 | 13.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
*Pharmacogenetics | 6 | 12.0 |
Macaca fascicularis | 3 | 1.0 |
Insects | 4 | 2.0 |
Phenobarbital/pharmacology | 5 | 8.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 2 | 13.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 3 | 42.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 5 | 17.0 |
Steroid Hydroxylases/antagonists & inhibitors | 5 | 50.0 |
Cytochrome P-450 Enzyme System/*drug effects | 4 | 30.0 |
Dapsone/*pharmacology | 2 | 20.0 |
Drug Combinations | 3 | 0.0 |
Pilot Projects | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 10 | 20.0 |
Cattle | 3 | 0.0 |
Hypoglycemic Agents/pharmacokinetics | 3 | 75.0 |
Protein Binding | 14 | 0.0 |
Tolbutamide/pharmacokinetics | 3 | 100.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 6 | 35.0 |
Liver/metabolism | 4 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 9 | 13.0 |
Binding, Competitive | 3 | 0.0 |
Chlorzoxazone/metabolism | 2 | 10.0 |
Cytochrome P-450 Enzyme System/metabolism | 12 | 4.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Phenacetin/metabolism | 2 | 18.0 |
Steroid Hydroxylases/metabolism | 11 | 17.0 |
Steroid Hydroxylases/*genetics/metabolism | 10 | 47.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Antihypertensive Agents/*pharmacokinetics | 2 | 33.0 |
Diclofenac/pharmacokinetics | 3 | 75.0 |
Losartan/*pharmacokinetics | 2 | 100.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 2 | 2.0 |
Anti-Bacterial Agents/*pharmacology | 4 | 3.0 |
Antibiotics, Antitubercular/*pharmacology | 2 | 14.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 3 | 21.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Chi-Square Distribution | 4 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Anticonvulsants/*pharmacokinetics | 2 | 20.0 |
Enzyme Inhibitors/pharmacokinetics | 2 | 66.0 |
Omeprazole/pharmacokinetics | 2 | 100.0 |
Phenytoin/*pharmacokinetics | 2 | 100.0 |
Catalysis/drug effects | 2 | 10.0 |
Methylation | 12 | 2.0 |
Microsomes, Liver/*enzymology/metabolism | 5 | 17.0 |
Enzyme Inhibitors/pharmacokinetics/*pharmacology | 2 | 18.0 |
Cyclooxygenase Inhibitors/*pharmacokinetics | 3 | 100.0 |
DNA, Complementary | 7 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 4 | 4.0 |
Rats, Sprague-Dawley | 11 | 0.0 |
Mephenytoin/*metabolism | 2 | 22.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
Steroid Hydroxylases/genetics/*metabolism | 4 | 28.0 |
Substrate Specificity/genetics | 2 | 4.0 |
Australia | 2 | 1.0 |
*Health Policy | 2 | 5.0 |
Cytochrome P-450 Enzyme System/drug effects/*physiology | 2 | 66.0 |
Fluvoxamine/*pharmacology | 3 | 12.0 |
Serotonin Uptake Inhibitors/*pharmacology | 4 | 13.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Phosphodiesterase Inhibitors/*metabolism | 2 | 66.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics | 2 | 40.0 |
Diclofenac/*pharmacokinetics | 2 | 66.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Isoenzymes/*metabolism | 12 | 4.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Microsomes, Liver/drug effects/*metabolism | 2 | 5.0 |
Spectrum Analysis, Mass | 9 | 1.0 |
Statistics | 3 | 0.0 |
Anticonvulsants/*metabolism | 3 | 37.0 |
Child, Preschool | 5 | 0.0 |
Phenytoin/*metabolism | 3 | 75.0 |
Brain/*enzymology | 2 | 1.0 |
*Pharmacokinetics | 3 | 6.0 |
Infusions, Intravenous | 2 | 0.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
Cytochrome P-450 Enzyme System/genetics | 5 | 4.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Metabolic Detoxication, Drug | 4 | 4.0 |
Odds Ratio | 3 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Hepatocytes/*enzymology/metabolism | 2 | 40.0 |
Immunoblotting | 4 | 0.0 |
Liver/enzymology/metabolism | 2 | 6.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 3 | 2.0 |
Receptors, Glucocorticoid/metabolism | 2 | 3.0 |
Receptors, Steroid/metabolism | 3 | 7.0 |
Binding Sites | 19 | 0.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 2 | 6.0 |
Molecular Structure | 7 | 0.0 |
Terpenes/pharmacology | 2 | 7.0 |
Biotransformation/drug effects | 2 | 6.0 |
Catalysis | 16 | 2.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 14 | 41.0 |
Biological Availability | 3 | 1.0 |
Computer Simulation | 2 | 0.0 |
Drug Design | 3 | 0.0 |
Enzyme Activation | 2 | 0.0 |
*Models, Molecular | 5 | 4.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Tolbutamide/*metabolism | 4 | 100.0 |
Acetonitriles/pharmacology | 2 | 50.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Ethanol/pharmacology | 2 | 3.0 |
Glucuronosyltransferase/*metabolism | 3 | 5.0 |
Hepatocytes/*drug effects/*enzymology | 3 | 42.0 |
Methanol/pharmacology | 2 | 18.0 |
Solvents/*pharmacology | 2 | 20.0 |
Ketoconazole/pharmacology | 7 | 7.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 3 | 33.0 |
Omeprazole/pharmacology | 3 | 25.0 |
Quinidine/pharmacology | 3 | 6.0 |
Algorithms | 5 | 1.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 3 | 7.0 |
Spectrophotometry, Ultraviolet | 6 | 3.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 2 | 11.0 |
Reproducibility of Results | 8 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Drug Evaluation, Preclinical/*methods | 4 | 12.0 |
DNA/genetics | 2 | 0.0 |
Japan | 13 | 0.0 |
Methyltransferases/genetics | 2 | 11.0 |
Polymorphism, Genetic/genetics | 7 | 1.0 |
Clinical Trials | 3 | 0.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 4 | 13.0 |
Anti-Infective Agents/*pharmacokinetics | 2 | 66.0 |
Microsomes/enzymology | 6 | 5.0 |
*Oxazolidinones | 2 | 50.0 |
Cytochrome P-450 CYP2D6/*genetics | 4 | 6.0 |
Drug Administration Schedule | 4 | 0.0 |
Benzimidazoles/pharmacology | 2 | 4.0 |
Liver/drug effects/enzymology | 4 | 6.0 |
Crystallography, X-Ray | 3 | 0.0 |
Heme/chemistry | 2 | 9.0 |
Hydrogen Bonding | 2 | 1.0 |
Ligands | 4 | 0.0 |
Progesterone/*metabolism | 2 | 5.0 |
Protein Conformation | 8 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Point Mutation | 4 | 0.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
Liver/enzymology | 6 | 1.0 |
Isoenzymes | 4 | 2.0 |
Silymarin/*pharmacology | 2 | 11.0 |
Tretinoin/*metabolism | 2 | 4.0 |
beta-Naphthoflavone/pharmacology | 2 | 6.0 |
Antidepressive Agents/*pharmacology | 2 | 7.0 |
Bicyclo Compounds | 2 | 33.0 |
*Hypericum | 2 | 22.0 |
Phloroglucinol/analogs & derivatives | 2 | 33.0 |
*Plants, Medicinal | 3 | 4.0 |
Citrus/*metabolism | 2 | 40.0 |
Coumarins/pharmacology | 2 | 10.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 2 | 7.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Microsomes/*enzymology | 3 | 6.0 |
Pharmaceutical Preparations/metabolism | 7 | 21.0 |
Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics | 2 | 100.0 |
Liver/drug effects/enzymology/metabolism | 2 | 16.0 |
Molecular Probes/metabolism | 2 | 66.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
*Phenotype | 3 | 1.0 |
Biotransformation/*genetics | 2 | 33.0 |
Antibodies, Blocking/pharmacology | 5 | 5.0 |
Cyclooxygenase Inhibitors/*metabolism | 2 | 66.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 3 | 18.0 |
Steroid Hydroxylases/biosynthesis/genetics/*metabolism | 2 | 66.0 |
Amino Acid Sequence | 13 | 0.0 |
Amino Acid Substitution | 6 | 0.0 |
Diclofenac/metabolism | 10 | 71.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Microsomes, Liver/*drug effects/*enzymology | 2 | 40.0 |
Steroid Hydroxylases/antagonists & inhibitors/*metabolism | 4 | 44.0 |
Linoleic Acid/*metabolism | 2 | 50.0 |
Cross Reactions | 3 | 0.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 4 | 26.0 |
Mixed Function Oxygenases/immunology/*metabolism | 2 | 33.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Steroid Hydroxylases/drug effects | 2 | 66.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
Immunohistochemistry | 3 | 0.0 |
Oxidoreductases, N-Demethylating/metabolism | 3 | 5.0 |
Isoenzymes/*antagonists & inhibitors | 6 | 18.0 |
Microsomes | 2 | 14.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/metabolism | 2 | 40.0 |
Diclofenac/*pharmacology | 3 | 75.0 |
Disulfiram/*pharmacology | 2 | 28.0 |
Erythromycin/*pharmacology | 3 | 14.0 |
Phenytoin/chemistry | 2 | 100.0 |
Progesterone/chemistry | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*chemistry/metabolism | 3 | 25.0 |
Steroid Hydroxylases/*chemistry/metabolism | 3 | 60.0 |
DNA, Complementary/*biosynthesis | 4 | 33.0 |
*Ginsenosides | 2 | 22.0 |
Panax/*chemistry | 2 | 18.0 |
Plant Extracts/*pharmacology | 4 | 5.0 |
Saponins/*pharmacology | 2 | 20.0 |
Cloning, Molecular | 4 | 0.0 |
DNA/blood | 3 | 1.0 |
Fluorescent Dyes | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Dogs | 5 | 0.0 |
Haplorhini | 2 | 0.0 |
Testosterone/metabolism | 3 | 2.0 |
Serotonin Uptake Inhibitors/metabolism | 2 | 66.0 |
Age Factors | 5 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Steroid Hydroxylases/chemistry | 2 | 50.0 |
Xenobiotics/*metabolism | 3 | 5.0 |
Anticoagulants/*metabolism | 2 | 6.0 |
Warfarin/*metabolism | 2 | 40.0 |
Benzodiazepines | 2 | 9.0 |
Frozen Sections | 2 | 2.0 |
B-Lymphocytes/enzymology | 2 | 5.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics | 2 | 40.0 |
*Drug Interactions | 5 | 21.0 |
Anticoagulants/*administration & dosage/therapeutic use | 2 | 33.0 |
Vitamin K/administration & dosage | 2 | 100.0 |
Warfarin/*administration & dosage/therapeutic use | 2 | 66.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 3 | 50.0 |
Fluvoxamine/pharmacology | 2 | 14.0 |
Asian Continental Ancestry Group/*genetics | 8 | 2.0 |
Benzoflavones/pharmacology | 4 | 8.0 |
Case-Control Studies | 5 | 0.0 |
Hemorrhage/chemically induced/*genetics | 2 | 100.0 |
Electrochemistry | 2 | 2.0 |
Mutation/genetics | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Microsomes/drug effects/enzymology/metabolism | 2 | 50.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 4 | 11.0 |
*Alleles | 4 | 0.0 |
*Mutation | 3 | 0.0 |
Isomerism | 3 | 1.0 |
Oxygen/metabolism | 2 | 0.0 |
Steroid Hydroxylases/antagonists & inhibitors/genetics/*metabolism | 3 | 75.0 |
Child | 11 | 0.0 |
Dealkylation | 6 | 10.0 |
Warfarin/chemistry/*pharmacokinetics | 3 | 100.0 |
Absorption | 2 | 1.0 |
Cystic Fibrosis/*metabolism | 2 | 4.0 |
Tissue Distribution | 3 | 0.0 |
Cell Differentiation | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Alkylation | 2 | 2.0 |
Cytochrome P-450 Enzyme System/chemistry/genetics/*metabolism | 2 | 25.0 |
Anti-Inflammatory Agents, Non-Steroidal/metabolism | 4 | 50.0 |
Sulfonamides/metabolism | 2 | 28.0 |
Warfarin/metabolism | 7 | 46.0 |
HIV Protease Inhibitors/*pharmacology | 2 | 7.0 |
Terpenes/*pharmacology | 3 | 15.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 3 | 12.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Blood Loss, Surgical/statistics & numerical data | 5 | 20.0 |
Blood Transfusion/utilization | 5 | 20.0 |
Cost-Benefit Analysis | 5 | 4.0 |
Hospital Costs/statistics & numerical data | 5 | 20.0 |
Length of Stay/statistics & numerical data | 5 | 14.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 5 | 21.0 |
*Outcome Assessment (Health Care) | 5 | 11.0 |
Perioperative Care | 5 | 20.0 |
Postoperative Complications/epidemiology | 5 | 10.0 |
Turkey/epidemiology | 5 | 6.0 |
Cytochrome P-450 CYP2E1/*antagonists & inhibitors/metabolism | 2 | 25.0 |
Linear Models | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/*genetics/metabolism | 2 | 66.0 |
Anti-Arrhythmia Agents/*pharmacokinetics | 2 | 33.0 |
Imidazoles/blood/*pharmacokinetics | 2 | 100.0 |
Cell Line, Tumor | 4 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Glucuronosyltransferase/metabolism | 2 | 7.0 |
Mutagens/*metabolism | 2 | 5.0 |
Steroid Hydroxylases/immunology/*metabolism | 2 | 100.0 |
Steroid Hydroxylases/*physiology | 2 | 33.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Orphenadrine/pharmacology | 2 | 50.0 |
Troleandomycin/pharmacology | 3 | 5.0 |
Sertraline | 3 | 30.0 |
Goats/*metabolism | 2 | 40.0 |
Ditiocarb/pharmacology | 2 | 11.0 |
Enzyme Induction/drug effects/physiology | 2 | 13.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Cyclophosphamide/*metabolism | 2 | 33.0 |
Ifosfamide/*metabolism | 2 | 50.0 |
Antibody Specificity | 4 | 0.0 |
Serotonin Uptake Inhibitors/pharmacokinetics/*pharmacology | 2 | 100.0 |
DNA/analysis | 4 | 0.0 |
Triazoles/*pharmacology | 2 | 15.0 |
Mixed Function Oxygenases/*genetics/metabolism | 2 | 4.0 |
Cytochrome P-450 CYP2D6/*metabolism | 3 | 8.0 |
Baculoviridae/genetics | 2 | 1.0 |
Biological Markers | 3 | 0.0 |
Anti-Infective Agents/adverse effects/*metabolism | 2 | 100.0 |
*Variation (Genetics) | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Models, Statistical | 2 | 1.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Antipsychotic Agents/chemistry/*metabolism | 2 | 100.0 |
Chromatography, High Pressure Liquid/methods | 4 | 2.0 |
Phenothiazines/chemistry/*metabolism | 2 | 100.0 |
Aspergillosis/*drug therapy | 2 | 66.0 |
Gene Expression/drug effects/genetics | 2 | 14.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Metabolic Clearance Rate/drug effects/physiology | 3 | 25.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Aspartic Acid/genetics/*metabolism | 2 | 50.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*chemistry | 2 | 40.0 |
Naproxen/metabolism | 2 | 40.0 |
Isoenzymes/immunology/*metabolism | 2 | 33.0 |
Antitussive Agents/metabolism | 2 | 50.0 |
Dextromethorphan/metabolism | 3 | 27.0 |
Midazolam/metabolism | 2 | 10.0 |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 10.0 |
Cytochrome P-450 CYP1A2 | 2 | 2.0 |
Cytochrome P-450 CYP2E1 | 2 | 1.0 |
Polymorphism, Genetic/drug effects/physiology | 3 | 100.0 |
Gene Frequency/drug effects/physiology | 2 | 100.0 |
Retrospective Studies | 4 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Exons | 3 | 0.0 |
Introns | 2 | 0.0 |
NADP/pharmacology | 2 | 9.0 |
DNA, Complementary/biosynthesis/genetics | 3 | 6.0 |
Diuretics/*pharmacokinetics | 2 | 100.0 |
Sulfonamides/*pharmacokinetics | 2 | 50.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 2 | 12.0 |
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects | 2 | 18.0 |
Amino Acids/chemistry | 2 | 1.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis | 2 | 18.0 |
Fluorometry | 2 | 2.0 |
Hepatocytes/*enzymology | 3 | 20.0 |
Anti-Inflammatory Agents, Non-Steroidal/*metabolism | 2 | 22.0 |
Quinolines/*pharmacokinetics | 2 | 20.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Cyclooxygenase Inhibitors/pharmacology | 3 | 4.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/genetics | 2 | 12.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 2 | 11.0 |
Isoenzymes/genetics | 2 | 0.0 |
Diclofenac/*urine | 2 | 100.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Intestines/*enzymology | 2 | 5.0 |
HL-60 Cells | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
*Thiazolidinediones | 2 | 2.0 |
Herb-Drug Interactions | 2 | 25.0 |
Hemorrhage/chemically induced | 2 | 12.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/metabolism | 2 | 28.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*chemistry/*metabolism | 2 | 50.0 |
Flurbiprofen/metabolism | 2 | 100.0 |
Losartan/*pharmacokinetics/urine | 2 | 100.0 |
Substrate Specificity/physiology | 2 | 9.0 |